


CLAIMS

1. A compound according to formula (Id)



- 5 wherein

R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or



R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or

R1 and R2 are both represented by substituent (i) below; or

R1 and R2 are both represented by substituent (ii) below; or

- 10 R1 is substituent (i) and R2 is substituent (ii); or

R1 is substituent (ii) and R2 is substituent (i);



- 15 wherein * indicates the attachment point; and

wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is selected from the

- 20 group consisting of:

(Id-ia): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-ib): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-iaa): (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl hydrogen sulfate;


(Id-iib): (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)hydrogen sulfate;

(Id-iaab): (2S,2'S,3S,3'S,4S,4'S,5R,5'R,6S,6'S)-6,6'-(((4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl)bis(oxy))bis(3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid);

(Id-iiab): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(hydrogen sulfate);

or a pharmaceutically acceptable salt of any of these compounds.


3. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-ia) below



(Id-ia)

or a pharmaceutically acceptable salt thereof.


4. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-ib) below



(Id-ib)

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iab) below




(Id-iab)

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iaa) below


68



(Id-iiia)

or a pharmaceutically acceptable salt thereof.

- 5 7. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iiib) below




(Id-iiib)

or a pharmaceutically acceptable salt thereof.

10


8. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iiab) below



(Id-iiab)

- 15 or a pharmaceutically acceptable salt thereof.

9. The compound according to any of claims 1-8 or a pharmaceutically acceptable salt thereof, wherein said compound is on an isolated form substantially free of the compound
5 of formula (I) below



(I).

10. The compound or pharmaceutically acceptable salt thereof according to any of
10 claims 1-9, wherein said compound or pharmaceutically acceptable salt thereof is in a solid form.
11. A pharmaceutically acceptable salt of a compound according to any of claims 1-10.
- 15 12. The compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, for use as a medicament.
- 20 13. A pharmaceutical composition comprising a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11, and one or more pharmaceutically acceptable excipients.
14. The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition is an oral pharmaceutical composition such as a tablet or a capsule for oral administration.

15. Use of a compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; wherein a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof is to be administered to a patient in need thereof.

16. Use of a compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.